A practical reference on receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
When diagnosed with myasthenia gravis, an individual can be stratified into distinct subgroups based on the clinical features and serological status, e.g., affected muscle group, age of onset, thymic abnormalities, and profile of serum autoantibodies. Based on the affected muscle group, people with myasthenia gravis can be sub-grouped into ocular myasthenia gravis or generalized myasthenia gravis. Ocular myasthenia gravis is characterized by exclusively ocular symptoms, droopy eyelids, or double vision. Generalized myasthenia gravis has muscle weakness with a variable combination of the bulbar, axial, or limb and respiratory muscles. People with myasthenia gravis can also be sub-grouped by the age of onset: juvenile-onset myasthenia gravis (onset age ≤ 18 years of age), early-onset MG (EOMG; 19–50 years of age), late-onset MG (LOMG; onset > 50 years of age), and very late-onset (VLOMG; onset age ≥ 65 years of age). The subgroup of the autoantibody profile includes AChR seropositive, MuSK seropositive, LRP4 seropositive, and agrin seropositive.
West married fellow scholar Stephanie Pickard in 1960 at Nottingham, after meeting her at a lecture given by Eduard Fraenkel at Corpus Christi College, Oxford, whose seminars he attended. He became a junior research fellow at St John's College from 1960 to 1963. His doctoral thesis, a commentary on Hesiod's Theogony, won the Conington Prize for the best classical dissertation of the year in 1965, and was edited as a printed book the following year. From the mid-sixties, West took especial interest in the relation of Greek literature to the Orient, and over several decades, culminating in his masterpiece The East Face of Helicon (1997), defended his view that Greek literature derives significant influences and inspiration from Near Eastern literature. He took up a position as tutorial fellow at University College, a position he filled from 1963 to 1974. In 1973 he became the second youngest person to be elected a Fellow of the British Academy, at the age of 35. He obtained a chair at Royal Holloway and Bedford New College, which he held from 1974 until 1991, when he became a fellow of All Souls College. West retired formally in 2004, but remained active in All Souls until the end of his life.
=== 68Ga radiolabeling === 68Ga-Trivehexin is a radioactive drug. The radioactive atom, gallium-68 (68Ga), decays with a half-life of approximately 68 min to the stable isotope zinc-68 (68Zn), to 89% by β+ decay whereby a positron with a maximum kinetic energy of 1.9 MeV is emitted (the remaining 11% are EC decays). Due to the short half-life, 68Ga-Trivehexin can not be manufactured long before use but the 68Ga has to be introduced into the molecule shortly before application. This process is referred to as radiolabeling, and is done by complexation of the trivalent cation 68GaIII by the TRAP chelator in Trivehexin. 68GaIII is usually obtained from a dedicated mobile radionuclide source, a Gallium-68 generator, in form of a solution in dilute (0.04–0.1 M) hydrochloric acid (frequently and imprecisely referred to as "68Ga chloride solution in HCl" despite it contains no species with a Ga–Cl bond but [68Ga(H2O)6]3+ complex hydrate cations). For radiolabeling, the pH of the 68Ga containing generator eluate has to be raised from its initial value (depending on HCl concentration, pH 1–1.5) to pH 2–3.5 using suitable buffers, such as sodium acetate. Then, Trivehexin (5–10 nmol) is added to the buffered 68Ga-containing solution, and the mixture is briefly heated to 50–100 °C (usually 2–3 min) to finalize the complexation reaction.
=== Europe === Germany: German Chancellor Olaf Scholz said that "Any resettlement plans, the idea that the citizens of Gaza will be expelled from there to Egypt or Jordan, is unacceptable." Russia: Russia's foreign ministry said that Trump's remarks were "shocking" and would add to tensions in the region. A Kremlin spokesperson said that the Kremlin was waiting for more details on the plan.
Alzheimer's disease (AD) can be definitively diagnosed only with histopathological findings; in the absence of autopsy or brain biopsy, clinical diagnoses of AD are "possible" or "probable", based on other findings. Up to 23% of those clinically diagnosed with AD may be misdiagnosed and may have pathology suggestive of another condition with symptoms that mimic those of AD.
Sources: en.wikipedia.org
Gamma-Dynacare Medical Laboratories is a Canadian medical laboratory services company based in Brampton, Ontario, Canada. Dynacare operates laboratories in Brampton, Bowmanville, London, Ottawa, Thunder Bay, Pointe-Claire, Laval, and Winnipeg. In addition to the main laboratories Dynacare operates patient services centers throughout Ontario, Quebec, Manitoba, Saskatchewan, Alberta and British Columbia. Dynacare is an operational partnership founded in 1997 as Gamma-Dynacare between: Dynacare Laboratories; Gamma North Peel Partnership Inc.; and Bio-Science Laboratory (Ontario) Limited. In 2002 Dynacare Laboratories (one of the Dynacare partners) was acquired by LabCorp for $480-million (U.S.) while also assuming Dynacare debt worth $205-million. In 2015, it rebranded itself back to Dynacare. In 2011 Dynacare acquired the medical laboratory division of Warnex Inc. (TSX:WNX) for $7.5 Million. In 2023 Dynacare acquired the medical laboratories in British Columbia known as Valley Medical Laboratories. This increased the Dynacare presence in British Columbia by adding about 12 locations in Kelowna and throughout the Okanagan Valley.
1994 Malaysian football scandal 1999 Chinese football match-fixing scandal 2001 Chinese football match-fixing scandal 2003–2009 Chinese football match-fixing scandals Apito Dourado (2004) – a match fixing scandal in Portuguese football involving FC Porto, Boavista, and União de Leiria. Bundesliga scandal (2005) – a match fixing scandal in German football centering on disgraced referee Robert Hoyzer. Caso Genoa (2005) Brazilian football match-fixing scandal (2005) – a match fixing scandal involving referees in Brazil. 2006 Calciopoli scandal – a match fixing scandal in Italian football involving several major teams, including three of the country's four qualifiers to the 2006–07 UEFA Champions League. In the Commonwealth of Independent States Cup 2006, the Armenian champion Pyunik refused to play with an Azerbaijani team, PFC Neftchi. The team Pyunik defeated the Ukrainian team Shakhtar Donetsk 3–1 in the quarter-final, when it already knew that in case of victory they would have to play against Neftchi. After the match, they told the referee they would not play against an Azerbaijani team and later that evening left Moscow on an airplane. The Russian Football Union gave Shakhtar Donetsk a technical victory 3–0 so they could play in the half-final instead of Pyunik, but Shakhtar Donetsk declined the offer stating that "[W]e would really want to play in the half-final, but we don't want to get there by any other way then sport".
==== Primeiro Comando da Capital ==== The Primeiro Comando da Capital (PCC) is one of Latin America's largest drug cartels. The organization primarily deals with drugs/arms trafficking, bank robberies and hijacking of armored trucks, as well as illegal gambling and smuggling (especially alcohol, tobacco, gold and timber). It is the biggest faction in Brazil, while also having a significant presence through the rest of South America, Portugal and the United States (mostly through the Brazilian-American community). In recent years, the organization has been reported to operate in many other countries as well, mostly through its alliances with foreign criminal groups (such as 'Ndrangheta in Italy, Group America in Serbia, Tren de Aragua in Venezuela, the Triads in China and the Jalisco Cartel in Mexico) and paramilitary groups (such as the FARC in Colombia and EPP in Paraguay). In recent years, there has even been reported activities of the group in West Africa (mostly aligned with local groups such as the Nigerian Mafia), Eastern Europe (through the Russian and Albanian mafias) and the Middle East (through the Turkish and Lebanese mafias). The group has also been alleged to have ties to the Yakuza in Japan and Hezbollah in Lebanon. PCC was originally founded on August 31, 1993, by eight prisoners at Taubaté Penitentiary, called "Piranhão" ("Big Piranha"), in the state of São Paulo. The group initially got together during a football game, where they founded a team called "Comando Capital" (Capital Command).
=== Federal, state, and county representation === Cresskill is located in the 5th Congressional District and is part of New Jersey's 39th state legislative district. For the 119th United States Congress, New Jersey's 5th congressional district is represented by Josh Gottheimer (D, Wyckoff). New Jersey is represented in the United States Senate by Democrats Cory Booker (Newark, term ends 2027) and Andy Kim (Moorestown, term ends 2031). For the 2026–2027 session, the 39th legislative district of the New Jersey Legislature is represented in the State Senate by Holly Schepisi (R, River Vale) and in the General Assembly by Robert Auth (R, Old Tappan) and John V. Azzariti (R, Saddle River). Bergen County is governed by a directly elected County Executive, with legislative functions performed by a Board of County Commissioners comprised of seven members who are elected at-large to three-year terms in partisan elections on a staggered basis, with either two or three seats coming up for election each November; a Chairman and Vice Chairman are selected from among its seven members at a reorganization meeting held every January. As of 2025, the county executive is James J. Tedesco III (D, Paramus), whose four-year term of office ends December 31, 2026. Bergen County's Commissioners are Chair Mary J. Amoroso (D, Mahwah, 2025), Vice Chair Steven A. Tanelli (D, North Arlington, 2027), Chair Pro Tem Joan Voss (D, Fort Lee, 2026), Rafael Marte (D, Bergenfield, 2026), Germaine M. Ortiz (D, Emerson, 2025), Thomas J. Sullivan Jr.
Other semi-aquatic mammals include beavers, hippopotamuses, otters and platypuses. Hippos are very large semi-aquatic mammals, and their barrel-shaped bodies have graviportal skeletal structures, adapted to carrying their enormous weight, and their specific gravity allows them to sink and move along the bottom of a river.
Sources: en.wikipedia.org
=== Film and other TV appearances === In addition to the game shows for which he became famous, Barker also hosted the annual/biennial Pillsbury Bake-Off (the bake-off occurred every two years starting in 1976). In 1978, he was the first host to have a male category champ. From 1969-1988 he also co-hosted CBS's coverage of the Rose Parade from Pasadena, California. On September 7, 2009, Barker was a special guest host for WWE Raw (called "The Price is Raw") in Rosemont, Illinois. Aired during a period when nearly every episode of the weekly wrestling show featured a celebrity guest host, with mixed results, Barker's appearance has been ranked the best of nearly 80 hosts. Barker also agreed to be a rotating guest co-host on The Huckabee Show, a daily TV talk show hosted by Mike Huckabee. Barker first appeared on the show on July 29, 2010. Barker's fame from his television hosting roles also saw him become a popular guest on other shows, including as a semi-regular panelist on the game shows Tattletales (1975–1976, with wife Dorothy Jo) and Match Game (1973–1980). Barker sat in Richard Dawson's former place during the first week after Dawson permanently left Match Game. Barker also made appearances on various talk shows such as: Dinah!, Larry King Live, The Arsenio Hall Show, Crook & Chase, Donny & Marie, The Rosie O'Donnell Show, The Ellen DeGeneres Show, The Wayne Brady Show, the Late Show with David Letterman, and The Late Late Show with Craig Ferguson.
== Nitrogen-15 == Nitrogen-15 is a rare stable isotope of nitrogen, comprising about 0.38%. Nitrogen-15 presents one of the lowest thermal neutron capture cross sections of all isotopes. Nitrogen-15 is frequently used in NMR (Nitrogen-15 NMR spectroscopy). Unlike the more abundant nitrogen-14, which has an integer nuclear spin and thus a quadrupole moment, 15N has a fractional nuclear spin of one-half, which offers advantages for NMR such as narrower line width. As most nitrogen NMR studies look at a single nitrogen atom in an organic molecule, isotopic labeling is feasible. Nitrogen-15 tracing is a technique used to study the nitrogen cycle.
In 1783, a series of earthquakes across Calabria caused around 50,000 deaths and damaged property. Many of the buildings were rebuilt thereafter. In 1733, after the outbreak of the War of Polish Succession, the Spanish Bourbons, allies of France against Austria, decided to attack Naples and secure that kingdom for Charles VII. Charles, who entered Naples in 1734, defeated the Austrian troops at the Battle of Bitonto, securing control of the kingdom, despite pockets of resistance, including Reggio Calabria, which fell on 20 June 1734. For ten years, however, the young Bourbon monarchy had to cope with the intrigues of the Austrian party present in Naples. This was particularly strong in Calabria, where the Duke of Verzino promised the Austrians that he could arm 12,000 rebels for their cause of reconquest during the War of Austrian Succession. The Duke had already armed an infantry regiment against the Infante in 1734. But after the Battle of Velletri in 1744, in which Charles VII repelled an Austrian invasion, the Austrian party disappeared, decimated by the Bourbon trials and inquisitions. Charles VII of Naples ascension aroused enthusiasm throughout the Mezzogiorno, as the population hoped that the resources of the Kingdom of Naples would be used for the development of state and social structures. Sicily, too, united politically with southern Italy; this was an advantage for Calabria, which moved to the center of the state structure. This was seen in Charles' popular journey in 1735, while on his way to Palermo to be crowned King of Sicily.
==== Llanos and tropical ecology ==== In February 1800, Humboldt and Bonpland departed the Caribbean coast, setting their sights on the Orinoco River. This important northern neighbor of the Amazon promised a gateway into the equatorial jungles, famed for their extraordinary biodiversity and dense tropical vegetation. For Humboldt, the journey offered a long-awaited opportunity to conduct magnetic measurements at latitudes where Earth’s magnetism would differ significantly from what he had found in Europe. The expedition also carried the excitement of possibly confirming the rumored connection between the Orinoco and Amazon or Rio Negro river systems—a geographical mystery that had fascinated explorers for years. The most direct route from Caracas to the Orinoco would have been to cross the southern mountain chain between Baruta and Salamanca, traverse the savannahs of Ocumare, and embark at Cabruta near the Rio Guarico’s mouth. However, this shortcut would have denied the travelers the chance to survey the most fertile and cultivated regions of the province—the valleys of Aragua—along with valuable opportunities to measure the elevation of the coastal mountain chain by barometer and to descend the Rio Apure to its meeting point with the Orinoco. From Puerto Cabello, Humboldt and Bonpland made their way across the coastal ranges and llanos towards Lake Valencia. The heat was so intense that they often rode at night to avoid the sun’s punishing rays.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.